Trine Larsen

Ms. Trine Larsen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2019 in Cancer Communications
Verified
Journal Article
Open access
PDF file
TLTrine Larsen
Trine Larsen
DHDianna Hussmann
Dianna Hussmann
ANAnders Lade Nielsen
Anders Lade Nielsen
Background: Programmed cell death ligand‐1 (PD‐L1) and ligand‐2 (PD‐L2) interaction with programmed cell death protein‐1 (PD‐1) represent an immune‐inhibiting checkpoint mediating immune evasion and is, accordingly, an important target for blockade‐based immunotherapy in cancer. In non‐small‐cell lung cancer (NSCLC), improved understanding of PD‐1 checkpoint blockade‐responsive biology and identification of biomarkers for prediction of a clinical response to immunotherapy is warranted. Thus, in the present study, we systematically described PD ‐ L1 and PD ‐ L2 expression correlated genes in NSCLC. Methods: We performed comparative retrospective analyses to identify PD ‐ L1 and PD ‐ L2 mRNA expression correlated genes in NSCLC. For this, we examined available datasets from the cancer cell line encyclopedia (CCLE) project lung non‐small‐cell (Lung_NSC) and the cancer genome atlas (TCGA) projects lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Results: Analysis of the CCLE dataset Lung_NSC identified expression correlation between PD ‐ L1 and PD ‐ L2 . Moreover, we identified expression correlation between 489 genes and PD ‐ L1 , 191 genes and PD ‐ L2 , and 111 genes for both. PD ‐ L1 and PD ‐ L2 also expression correlated in TCGA datasets LUAD and LUSC. In LUAD, we identified expression correlation between 257 genes and PD ‐ L1 , 914 genes and PD ‐ L2 , and 211 genes for both. In LUSC, we identified expression correlation between 26 genes and PD ‐ L1 , 326 genes and PD ‐ L2 , and 13 genes for both. Only a few genes expression correlated with PD ‐ L1 and PD ‐ L2 across the CCLE and TCGA datasets. Expression of Interferon signaling‐involved genes converged in particular with the expression correlated genes for PD ‐ L1 in Lung_NSC, for PD ‐ L2 in LUSC, and for both PD ‐ L1 and PD ‐ L2 in LUAD. In LUSC, PD ‐ L1 , and to a lesser extent PD ‐ L2, expression correlated with chromosome 9p24 localized genes, indicating a chromosome 9p24 topologically associated domain as an important driver of in particular LUSC PD ‐ L1 expression. Expression correlation analyses of the PD‐L1 and PD‐L2 receptors programmed cell death protein‐1 (PD‐1), Cluster of differentiation 80 (CD80), and Repulsive guidance molecule B (RGMB) showed that PD ‐ 1 and CD80 expression correlated with both PD ‐ L1 and PD ‐ L2 in LUAD. CD80 expression correlated with PD ‐ L2 in LUSC. Conclusions: We present gene signatures associated with PD ‐ L1 and PD ‐ L2 mRNA expression in NSCLC which could possess importance in relation to understand PD‐1 checkpoint blockade‐responsive biology and development of gene signature based biomarkers for predicting clinical responses to immunotherapy.

22 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TLTrine Larsen
Trine Larsen
NDNina Dybdal
Nina Dybdal
TDTina F. Daugaard
Tina F. Daugaard
JLJohanne Lade-Keller
Johanne Lade-Keller
LLLin Lin
Lin Lin
ANAnders Lade Nielsen
Anders Lade Nielsen
Immunotherapy targeting the interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) is a treatment option for patients with non-small-cell lung cancer (NSCLC). The expression of PD-L1 by the NSCLC cells determines treatment effectiveness, but the relationship between PD-L1 DNA methylation and expression has not been clearly described. We investigated PD-L1 DNA methylation, mRNA expression, and protein expression in NSCLC cell lines and tumor biopsies. We used clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) to modify PD-L1 genetic contexts and endonuclease deficient Cas9 (dCas9) fusions with ten-eleven translocation methylcytosine dioxygenase 1 (TET1) and DNA (cytosine-5)-methyltransferase 3A (DNMT3A) to manipulate PD-L1 DNA methylation. In NSCLC cell lines, we identified specific PD-L1 CpG sites with methylation levels inversely correlated with PD-L1 mRNA expression. However, inducing PD-L1 mRNA expression with interferon-γ did not decrease the methylation level for these CpG sites, and using CRISPR-Cas9, we found that the CpG sites did not directly confer a negative regulation. dCas9-TET1 and dCas9-DNMT3A could induce PD-L1 hypo- and hyper-methylation, respectively, with the latter conferring a decrease in expression showing the functional impact of methylation. In NSCLC biopsies, the inverse correlation between the methylation and expression of PD-L1 was weak. We conclude that there is a regulatory link between PD-L1 DNA methylation and expression. However, since these measures are weakly associated, this study highlights the need for further research before PD-L1 DNA methylation can be implemented as a biomarker and drug target for measures to improve the effectiveness of PD-1/PD-L1 immunotherapy in NSCLC.

15 December 2023 in Cells
Verified
Journal Article
Open access
PDF file
TLTrine Larsen
Trine Larsen
CMChristoffer Trier Maansson
Christoffer Trier Maansson
TDTina F. Daugaard
Tina F. Daugaard
BABrage Storstein Andresen
Brage Storstein Andresen
BSBoe Sorensen
Boe Sorensen
ANAnders Lade Nielsen
Anders Lade Nielsen
Immunotherapy using checkpoint inhibitors targeting the interaction between PD-1 on T cells and PD-L1 on cancer cells has shown significant results in non-small-cell lung cancer (NSCLC). Not all patients respond to the therapy, and PD-L1 expression heterogeneity is proposed to be one determinant for this. The alternative processing of PD-L1 RNA, which depends on an alternative poly-A site in intron 4, generates a shorter mRNA variant (PD-L1v4) encoding soluble PD-L1 (sPD-L1), relative to the canonical PD-L1v1 mRNA encoding membrane-associated PD-L1 (mPD-L1). This study aimed to identify factors influencing the ratio between these two PD-L1 mRNAs in NSCLC cells. First, we verified the existence of the alternative PD-L1 RNA processing in NSCLC cells, and from in silico analyses, we identified a candidate list of regulatory factors. Examining selected candidates showed that CRISPR/Cas9-generated loss-of-function mutations in CDK12 increased the PD-L1v4/PD-L1v1 mRNA ratio and, accordingly, the sPD-L1/mPD-L1 balance. The CDK12/13 inhibitor THZ531 could also increase the PD-L1v4/PD-L1v1 mRNA ratio and impact the PD-L1 transcriptional response to IFN-γ stimulation. The fact that CDK12 regulates PD-L1 transcript variant formation in NSCLC cells is consistent with CDK12’s role in promoting transcriptional elongation over intron-located poly-A sites. This study lays the groundwork for clinical investigations to delineate the implications of the CDK12-mediated balancing of sPD-L1 relative to mPD-L1 for immunotherapeutic responses in NSCLC.